LYON, France--(BUSINESS WIRE)-- POXEL SA (Euronext – POXEL - FR0012432516), a biopharmaceutical company focused on the development of innovative drugs to treat type 2 diabetes, today announced that the Company will make a presentation at the 28th Annual ROTH Conference to be held on March 13 - 16, 2016 at the Ritz Carlton Hotel, Dana Point, California.
The Company’s management will present on Tuesday, March 15, 2016 at 12:00 p.m. PT / 3:00 p.m. EST/ 9:00 p.m. CET.
The simultaneous live webcast, including a slide presentation, can be accessed by logging onto http://wsw.com/webcast/roth30/register.aspx?conf=roth30&page=poxel.pa&url=http://wsw.com/webcast/roth30/poxel.pa/index.aspx or on the Poxel website at www.poxel.com. A replay of the webcast will be available on Poxel’s website shortly after the conclusion of the call and will be archived there for 30 days following the call.
About Poxel
Poxel uses its unique development expertise in
metabolism to advance a pipeline of truly novel products currently
focused on type 2 diabetes. Our first-in-class lead product, Imeglimin,
targeting mitochondrial dysfunction, has successfully completed Phase 2
development in the US and EU and has started Phase 2b development in
Japanese patients. We are advancing our second program, PXL770, a direct
AMPK activator, through clinical proof-of-concept. We will generate
further growth through strategic partnerships and pipeline development.
(Euronext: POXEL, www.poxel.com)
View source version on businesswire.com: http://www.businesswire.com/news/home/20160303006414/en/
Investor relations / Media - EU/US
MacDougall Biomedical
Communications
Gretchen Schweitzer, + 49 89 2424 3494
or
Stephanie
May, + 49 172 861 8540
smay@macbiocom.com
or
Investor
relations / Media - France
NewCap
Florent Alba/Nicolas
Mérigeau, + 33 1 44 71 98 55
poxel@newcap.fr
Source: Poxel
Released March 4, 2016